UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A fatal unsuspected case of acquired A hemophilia. Misleading role of therapy with acetylsalicylic acid?

Internal and emergency medicine, 2021-11, Vol.16 (8), p.2339-2340

2021

Volltextzugriff (PDF)

Correction to: A fatal unsuspected case of acquired A hemophilia. Misleading role of therapy with acetylsalicylic acid?

Internal and emergency medicine, 2021-11, Vol.16 (8), p.2343-2343

2021

Volltextzugriff (PDF)

Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency

Reviews on recent clinical trials, 2023-01, Vol.18 (4), p.300-303

2023

Volltextzugriff (PDF)

A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature

Clinical case reports, 2022-04, Vol.10 (4), p.e05379-n/a

2022

Volltextzugriff (PDF)

A BRAF -Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin

Turkish journal of haematology, 2020-11, Vol.37 (4), p.286-309

2020

Volltextzugriff (PDF)

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients

Frontiers in oncology, 2020-12, Vol.10, p.570187-570187

2020

Volltextzugriff (PDF)

A BRAF-Negative Classic Hairy Cell Leukemia Patient with LongLasting Complete Remission after Rituximab and Pentostatin

Turkish journal of haematology, 2020-11, Vol.37 (4), p.286-287

2020

Volltextzugriff (PDF)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice

Journal of personalized medicine, 2020-09, Vol.10 (3), p.120

2020

Volltextzugriff (PDF)

Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network)

Journal of personalized medicine, 2022-03, Vol.12 (3), p.484

2022

Volltextzugriff (PDF)

Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia

International immunopharmacology, 2017-03, Vol.44, p.38-42

2017

Volltextzugriff (PDF)

Switch of TPO-Mimetics in Patients with Immune Thrombocytopenia

Blood, 2017-12, Vol.130, p.4849-4849

2017

Volltextzugriff (PDF)

CLL-251: Venetoclax for CLL Patients Outside Clinical Trials: An Italian Real-Life Experience

Clinical lymphoma, myeloma and leukemia, 2020-09, Vol.20, p.S225-S226

2020

Volltextzugriff (PDF)

First reported case of secondary mixed phenotype acute leukemia after multiple myeloma

American journal of blood research, 2021-01, Vol.11 (1), p.123-131

2021

Volltextzugriff (PDF)

LONG TERM SAFETY AND EFFICACY OF DARATUMUMAB RAPID INTRAVENOUS INFUSION (90 MINUTES) AFTER THE THIRD DOSE IN MULTIPLE MYELOMA PATIENTS

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e147-e148

2019

Volltextzugriff (PDF)

Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide

Leukemia & lymphoma, 2015-08, Vol.56 (8), p.2388-2391

2015

Volltextzugriff (PDF)

Corrigendum to “Rapid infusions of human normal immunoglobulin 50 g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia” [Int. Immunopharmacol. 44 (2017) 38–42]

International immunopharmacology, 2018-04, Vol.57, p.201-201

2018

Volltextzugriff (PDF)

Corrigendum to “Rapid infusions of human normal immunoglobulin 50 g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia” [Int. Immunopharmacol. 44 (2017) 38–42]

International immunopharmacology, 2018-04, Vol.57, p.202

2018

Volltextzugriff (PDF)

DART4MM: Daratumumab as Consolidation Therapy in Patients who Already Achieved Optimal Response /MRD Positivity by Next Generation Flow (NGF): Preliminary Results of a Phase 2 Multicenter Study

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e161-e162

2019

Volltextzugriff (PDF)

Rapid infusions of human normal immunoglobulin 50 g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia

International immunopharmacology, 2017-03, Vol.44, p.38

2017

Volltextzugriff (PDF)

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONYResearch in context

EClinicalMedicine, 2023-11, Vol.65, p.102307

2023

Volltextzugriff (PDF)

S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY

HemaSphere, 2023-08, Vol.7 (S3), p.e24596f8-n/a

2023

Volltextzugriff (PDF)

Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42]

International immunopharmacology, 2018-04, Vol.57, p.201-201

2018

Volltextzugriff (PDF)

Evaluating the risk of venous thromboembolism in medical patients: which criteria?

The American journal of emergency medicine, 2012-03, Vol.30 (3), p.504-505

2012

Volltextzugriff (PDF)

A fatal unsuspected case of acquired A hemophilia. Misleading role of therapy with acetylsalicylic acid?

Internal and emergency medicine, 2021, Vol.16 (8), p.2339-2340

2021

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(24)
Berichte
(2)

Sprache

Englisch
(26)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Humans
(5)
General & Internal Medicine
(4)
Medicine, General & Internal
(4)
Patients
(4)
Aged
(3)
Chronic Lymphocytic Leukemia
(3)
Female
(3)
Hairy Cell Leukemia
(3)
Hematology
(3)
Immunoglobulins
(3)
Male
(3)
Multiple Myeloma
(3)
Rapid Infusion
(3)
Adult
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Biopsy
(2)
Bone Marrow
(2)
Braf
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A fatal unsuspected case of acquired A hemophilia. Misleading role of therapy with acetylsalicylic acid?

Correction to: A fatal unsuspected case of acquired A hemophilia. Misleading role of therapy with acetylsalicylic acid?

Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency

A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature

A BRAF -Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients

A BRAF-Negative Classic Hairy Cell Leukemia Patient with LongLasting Complete Remission after Rituximab and Pentostatin

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice

Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network)

Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia

Switch of TPO-Mimetics in Patients with Immune Thrombocytopenia

CLL-251: Venetoclax for CLL Patients Outside Clinical Trials: An Italian Real-Life Experience

Minimal Residual Disease (MRD) at 10-6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment For Multiple Myeloma Eradication)

First reported case of secondary mixed phenotype acute leukemia after multiple myeloma

LONG TERM SAFETY AND EFFICACY OF DARATUMUMAB RAPID INTRAVENOUS INFUSION (90 MINUTES) AFTER THE THIRD DOSE IN MULTIPLE MYELOMA PATIENTS

Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide

Corrigendum to “Rapid infusions of human normal immunoglobulin 50 g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia” [Int. Immunopharmacol. 44 (2017) 38–42]

Corrigendum to “Rapid infusions of human normal immunoglobulin 50 g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia” [Int. Immunopharmacol. 44 (2017) 38–42]

DART4MM: Daratumumab as Consolidation Therapy in Patients who Already Achieved Optimal Response /MRD Positivity by Next Generation Flow (NGF): Preliminary Results of a Phase 2 Multicenter Study

Rapid infusions of human normal immunoglobulin 50 g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia

Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONYResearch in context

S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY

Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42]

Evaluating the risk of venous thromboembolism in medical patients: which criteria?

A fatal unsuspected case of acquired A hemophilia. Misleading role of therapy with acetylsalicylic acid?

Suchergebnisse filtern